Power Law company profile

Entrada Therapeutics

Biotech & Life Sciences · Boston, United States · Founded 2016 · IPO 2021 Thoroughbred

Aims to treat devastating diseases through the intracellular delivery of biologics

Valuation

$279M

Market cap · May/2026

Revenue

$25M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

14 investors on Entrada Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage

MPM BioImpact

Agent Capital

5AM Ventures

Roche Venture Fund

Series B+ 10 investors entered at this stage

Cure Duchenne

Wellington Management

Point72 Ventures

Moore Strategic Ventures

Goldman Sachs

Greenspring Associates

TCGX

MRL Ventures

Qatar Investment Authority

Redmile Group

Global footprint

Where Entrada Therapeutics has talent and traffic

AI talent share

0.5% of workforce is AI talent
(1 of 201 staff)

Core AI00%

Other AI10.5%

Non-AI workforce20099.5%

Workforce by country

4 countries with
team presence

🇺🇸 United States98.6%

🇮🇹 Italy0.6%

🇬🇧 United Kingdom0.6%

🇮🇪 Ireland0.6%

4 countries shown

Web traffic by country

7.3K monthly visits
across markets

🇺🇸 United States67.1%

🇬🇧 United Kingdom20.5%

🇮🇳 India12.3%

Top 3 markets shown

Market sentiment

What the market is saying about Entrada Therapeutics

An AI-synthesized read of the highest-engagement posts about Entrada Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Entrada Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles